Health TrialsbyHealthPanel

Clonal Hematopoiesis of Immunological Significance

ConditionsImmune System DiseasesAutoimmune DiseasesInflammationAutoinflammatory DiseasesVexas SyndromeHematopoiesis ClonalClonal Hematopoiesis of Indeterminate PotentialHematologic DiseasesMyelodysplastic-Myeloproliferative DiseasesLeukemia Myelomonocytic ChronicMyelodysplastic SyndromesMyeloproliferative DisordersLymphoproliferative DisordersLymphomaLeukemiaMonoclonal Gammopathy of Undetermined Significance
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAssistance Publique - Hôpitaux de Paris

About this trial

Ambispective, national, multicenter observational cohort study aimed at characterizing the satellite dysimmune manifestations of clonal hematopoiesis, including Vexas (Vacuoles, E1 enzyme, X-linked, Autoinflammatory and Somatic) syndrome.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age >=18 years old;

Confirmed dysimmune manifestations: clinical or biological abnormality or systemic disease;

Presence or absence of myeloid or lymphoid blood disease according to World Health Organization (WHO) classification

Disqualifiers

Persons benefiting from special protection: adults under guardianship and curatorship;

People hospitalized without their consent and not protected by law; persons deprived of liberty;

Persons not affiliated to the social security system

Trial population

The research concerns : * patients whose inflammatory disease without or with haemopathy is already known when the cohort is set up, and for whom data will be collected retrospectively and then prospectively * incident cases identified after the cohort was set up.

Trial design

Design model

Cohort

Time perspective

Other

Treatments tested in this trial

  • observational cohort study

    Other intervention

    observational cohort study

Treatment groups

5,000 Participants
are divided into 1 treatment group
Group A: Dysimmune manifestations with or without clonal hematopoiesis1 intervention

Trial outcomes

Primary outcomes

1

Incidence of dysimmune manifestations associated with hematological disorders

Number of new cases

Time frame
Baseline

Secondary outcomes

1

VEXAS syndrome

Number of patients with VEXAS syndrome

Time frame
10 years
2

Dysimmune manifestations other than VEXAS syndrome

Number of patients with dysimmune manifestations other than VEXAS syndrome

Time frame
10 years
3

Myeloid hemopathy

Number of patients with myeloid hemopathy

Time frame
10 years
4

Lymphoid hemopathy

Number of patients with lymphoid hemopathy

Time frame
10 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Assistance Publique - Hôpitaux de Paris

Lead sponsor

Sorbonne University

Collaborator

Institut National de la Santé Et de la Recherche Médicale, France

Collaborator

Club MINHEMON (MEDECINE INTERNE, HEMATO ET ONCO)

Collaborator

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: